Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Shares Outstanding for 16 consecutive years, with $138.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2256.28% to $138.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $138.9 million through Dec 2025, up 2256.28% year-over-year, with the annual reading at $138.9 million for FY2025, 2256.28% up from the prior year.
  • Shares Outstanding for Q4 2025 was $138.9 million at Plus Therapeutics, up from $1952.0 in the prior quarter.
  • The five-year high for Shares Outstanding was $138.9 million in Q4 2025, with the low at $1952.0 in Q1 2021.
  • Average Shares Outstanding over 5 years is $15.4 million, with a median of $2.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding plummeted 100.0% in 2023, then skyrocketed 452265500.0% in 2024.
  • Over 5 years, Shares Outstanding stood at $15.4 million in 2021, then crashed by 99.99% to $1952.0 in 2022, then soared by 231593.44% to $4.5 million in 2023, then soared by 30.37% to $5.9 million in 2024, then surged by 2256.28% to $138.9 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $138.9 million, $131.9 million, and $92.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.